Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Moodys
Harvard Business School
Dow
McKinsey

Last Updated: January 27, 2023

Details for Patent: 7,253,286


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,253,286 protect, and when does it expire?

Patent 7,253,286 protects LENVIMA and is included in one NDA.

This patent has fifty-one patent family members in twenty-three countries.

Summary for Patent: 7,253,286
Title:Nitrogen-containing aromatic derivatives
Abstract: Compounds represented by the following general formula: ##STR00001## [wherein A.sup.g is an optionally substituted 5- to 14-membered heterocyclic group, etc.; X.sup.g is --O--, --S--, etc.; Y.sup.g is an optionally substituted C.sub.6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and T.sup.g1 is a group represented by the following general formula: ##STR00002## (wherein E.sup.g is a single bond or --N(R.sup.g2)--, R.sup.g1 and R.sup.g2 each independently represent a hydrogen atom, an optionally substituted C.sub.1-6 alkyl group, etc. and Z.sup.g represents a C.sub.1-8 alkyl group, a C.sub.3-8 alicyclic hydrocarbon group, a C.sub.6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.
Inventor(s): Funahashi; Yasuhiro (Nagoya, JP), Tsuruoka; Akihiko (Tsukuba, JP), Matsukura; Masayuki (Tsukuba, JP), Haneda; Toru (Ushiku, JP), Fukuda; Yoshio (Tsukuba, JP), Kamata; Junichi (Tsukuba, JP), Takahashi; Keiko (Ushiku, JP), Matsushima; Tomohiro (Ushiku, JP), Miyazaki; Kazuki (Tsukuba, JP), Nomoto; Ken-ichi (Tsukuba, JP), Watanabe; Tatsuo (Inzai, JP), Obaishi; Hiroshi (Tsukuba, JP), Yamaguchi; Atsumi (Tsukuba, JP), Suzuki; Sachi (Tsuchiura, JP), Nakamura; Katsuji (Tsukuba, JP), Mimura; Fusayo (Tsukuba, JP), Yamamoto; Yuji (Tsukuba, JP), Matsui; Junji (Toride, JP), Matsui; Kenji (Tsukuba, JP), Yoshiba; Takako (Tsukuba, JP), Suzuki; Yasuyuki (Kagamigahara, JP), Arimoto; Itaru (Tsukuba, JP)
Assignee: Eisai Co., Ltd (Bunkyo-ku, Tokyo, JP)
Application Number:10/420,466
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,253,286

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-001 Feb 13, 2015 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-002 Feb 13, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,253,286

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
JapanP2000-320420Oct 20, 2000
JapanP2000-386195Dec 20, 2000
JapanP2001-046685Feb 22, 2001

International Family Members for US Patent 7,253,286

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 355275 See Plans and Pricing
Austria 399766 See Plans and Pricing
Austria 419239 See Plans and Pricing
Australia 2001295986 See Plans and Pricing
Australia 2006203099 See Plans and Pricing
Australia 2006236039 See Plans and Pricing
Australia 9598601 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Boehringer Ingelheim
McKinsey
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.